Cardiovascular calcification refers to the buildup of calcium phosphate in the walls of the arteries and heart valves. Also known as the hardening of the arteries, this condition can lead to serious cardiovascular events including heart disease. Atherosclerosis and chronic kidney disease are increasingly contributing to the rising cases of vascular calcification, which is likely to augment the demand for effective cardiovascular calcification drugs.
The Cardiovascular Calcification Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into cardiovascular calcification therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for cardiovascular calcification. The cardiovascular calcification report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The cardiovascular calcification pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from the condition, and alignment with cardiovascular calcification treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to cardiovascular calcification.
Cardiovascular calcification is characterized by mineral deposits in heart valve leaflets and vessel walls. Coronary artery calcification causes the arteries to become stiff, which puts the affected patient at a higher risk for cardiovascular issues. According to a cross-sectional study published in BMC Cardiovascular Disorders (2022), the overall prevalence of vascular calcification was estimated to be 24.39% in the general population.
Cardiovascular calcification therapeutics include Vitamin D receptor agonists that can help in the treatment of vitamin D deficiency and secondary hyperparathyroidism, thereby preventing calcification. Calcimimetics, sodium thiosulfate, and calcium channel blockers are some of the common medications for addressing vascular calcification. Additionally, advancements in imaging techniques and biomarkers, along with adherence to cardiovascular calcification treatment guidelines, are expected to improve patient outcomes and aid pipeline expansion in the coming years.
Cardiovascular calcification is age- and gender-dependent. Studies show that over 90% of men and 67% of women who are older than 70 years are affected by coronary artery calcification. It is also observed that people with chronic kidney disease, diabetes, high body mass index, or high blood pressure, among others, are more prone to developing cardiovascular calcification.
This section of the report covers the analysis of cardiovascular calcification drug candidates based on several segmentations including:
By Phase
By Drug Class
By Route of Administration
The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total clinical trials, with a substantial number of cardiovascular calcification emerging drugs undergoing clinical development.
The drug molecule categories covered under cardiovascular calcification pipeline analysis include monoclonal antibody, peptides, polymer, small molecule, and gene therapy. The cardiovascular calcification report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for cardiovascular calcification.
The EMR report for the cardiovascular calcification drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed cardiovascular calcification therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in cardiovascular calcification clinical trials:
Major drugs currently in the drug pipeline are as follows:
Sponsored by REDNVIA Co., Ltd., the objective of this randomized, double-blinded, multicenter clinical trial is to investigate the efficacy and safety of the cardiovascular calcification drug candidate Evogliptin in patients with calcific aortic valve disease with mild to moderate aortic stenosis. The study is under Phase II/III clinical development and has an estimated 867 participants.
The purpose of this double-blind randomized controlled trial is to examine the efficacy of metformin on peripheral arterial calcification in type 1 diabetes patients. The interventional study has enrolled about 230 subjects and is expected to be completed by February 2025.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Cardiovascular Calcification Drug Report provides a strategic overview of the latest and future landscape of treatments for cardiovascular calcification. it provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within cardiovascular calcification pipeline insights.
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share